Citation Impact
Citing Papers
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
2016 Standout
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
2013 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
2008 Standout
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysis
2013
Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
2010
New Antithrombotic Drugs
2008
New Antithrombotic Drugs
2012
Antithrombotic Therapy for VTE Disease
2016 Standout
Conflict of Interest in the Assessment of Thromboprophylaxis After Total Joint Arthroplasty
2012
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement
2010
Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy
2009 Standout
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
2010 StandoutNobel
Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban
2010
Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy
2018
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Factor Xa Inhibitors: Next-Generation Antithrombotic Agents
2010
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Betrixaban (PRT054021): pharmacology, Dose Selection and Clinical Studies
2013
Industry sponsorship and research outcome
2017 Standout
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
2011 Standout
Works of Michael Huo being referenced
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)
2008